LONDON, June 28, 2017 /PRNewswire/ -- "Global Hepatitis Drug Market & Clinical Trials Insight 2023" report gives comprehensive insight on various clinical and non-clinical advancements in the global Hepatitis drug market. Currently, there are 321 Hepatitis drugs in clinical pipeline and 110 Hepatitis drugs are commercially available in the market. Hepatitis drug clinical trials landscape is dominated by Hepatitis C drug with 145 drugs in various phases of development and 25 drugs commercially available in the market. The overall Hepatitis drug revenues are expected to surpass US$ 70 Billion by 2023 with major share accounted by Hepatitis C drugs. Download the full report: https://www.reportbuyer.com/product/4962335/"Global Hepatitis Drug Market & Clinical Trials Insight 2023" report highlights:• Prevalence of Hepatitis Infection• Available Drug Classes for Hepatitis Drug• Global Hepatitis Drug Market Analysis• Global Hepatitis (A,B,C,D & E) Drug Clinical Pipeline Insight• Marketed Hepatitis Drug Clinical Insight by Drug Class• Future Perspective of Hepatitis TherapeuticsHepatitis virus infection lies among primary public health threats globally and is basically a main reason for the development of liver cirrhosis and hepatocellular carcinoma. The incidence and prevalence of hepatitis viral infection is growing and increases the burden. However, the worldwide remains unknown due to heterogeneous registration and case definitions. There are several subcategories of viruses which cause the infection or inflammation to liver and these subgroups are hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus and hepatitis E virus. The investigation for other subcategory of viruses is ongoing. Hepatitis B virus and hepatitis C virus are main leading causes of liver diseases. The past two decades have witnessed substantial progress in the treatment of hepatitis virus infection and it includes the introduction of nucleotides and nucleoside analogues, interferons, toll like receptors and protease inhibitors which revolutionized the hepatitis disease management. With the recent dramatic progress in development of potent antiviral drugs for chronic hepatitis virus infection, virological responses are achievable in almost all patients. Most clinical practice guidelines strongly recommended the treatment of patients with antiviral agents if they have proper indications. The main aim of antiviral treatment is to inhibit the hepatitis virus replication and improve the liver pathology but it rarely cures chronic hepatitis infection. The global hepatitis drug market is expected to surpass USD 70 Billion by 2023 with the rising number of infected population, growing consumption of alcohol and drugs and the improvement in the access to hepatitis medicines. The introduction of generic drugs of hepatitis has also changed the market dynamics across the globe. With the increase of people being able to afford the generic versions, the usage rates of drugs are expected to grow rapidly over the next few years.Download the full report: https://www.reportbuyer.com/product/4962335/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com
For more information: Sarah Smith
Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-hepatitis-drug-market--clinical-trials-insight-2023-300481144.html
SOURCE ReportBuyer
